| Document |
Document Title |
|
WO/2020/036310A1 |
The present specification relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside
-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, and pharmaceutically acceptable salts the...
|
|
WO/2020/033412A1 |
The present disclosure relates to compositions and methods for treating iron overload. In particular, the methods for treating iron overload include administering to a patient an HIV protease inhibitor and an iron chelator. Iron overload...
|
|
WO/2020/031955A1 |
The purpose of the present invention is to provide an agent for suppressing heat-resistant acidophilic bacteria, said agent comprising as an active ingredient a substance which has an effect of suppressing the growth of heat-resistant ac...
|
|
WO/2020/027304A1 |
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...
|
|
WO/2020/024773A1 |
Disclosed in the present invention is use of YAP and FOXD1 in preparation of a product for treating and/or preventing osteoarthritis in animals. The present invention found that YAP and FOXD1 have the following functions: treating and/or...
|
|
WO/2020/024774A1 |
Disclosed by the present invention is an application of DGCR8 in the preparation of a product for treating and/or preventing osteoarthritis in animals. The present invention finds that DGCR8 has the following functions: treating and/or p...
|
|
WO/2020/016593A1 |
The invention relates to compositions comprising a chelating agent bound to an extended surface biologically inert substrate, methods of producing said compositions and uses of said compositions in treating heavy metal poisoning, as diet...
|
|
WO/2020/005097A1 |
The invention relates to the pharmaceutical field and concerns a composition that possesses antiviral, antitumor, immunomodulatory, actoprotective, antimutagenic and antioxidant activity and can be used as an adjunct to antitumor therapy...
|
|
WO/2020/001203A1 |
Disclosed in the present invention are a compound amino acid vitamin injection solution and use thereof. The compound amino acid vitamin injection solution comprises per 1000 ml: 5-40 g of L-leucine, 2-30 g of L-isoleucine, 2-30 g of L-v...
|
|
WO/2020/004858A1 |
The present invention relates to a diabetes-alleviating or antioxidant composition comprising yeast extract and a method for preparing the yeast extract
|
|
WO/2019/246094A1 |
The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the...
|
|
WO/2019/182318A9 |
The invention relates to a method for preparing compound K by using ginseng sprouts, and an antioxidative and antibacterial composition containing compound K prepared thereby. In the present invention, various ginsenosides contained in g...
|
|
WO/2019/245073A1 |
The present invention relates to an antioxidant composition. More particularly, the present invention comprises an antioxidant composition in which glutathione with a molar concentration of 1 pM to 100 mM and an antioxidant material with...
|
|
WO/2019/241584A1 |
The present disclosure relates to a dog food composition comprising from about 10% by weight to about 20% by weight of fat, from about 5% by weight to about 15% by weight of fibers and from about 30% by weight to about 60% by weight prot...
|
|
WO/2019/241728A1 |
Disclosed herein are therapeutic agents capable of increasing the expression level of an epigenetic marker described herein. Also described herein are therapeutic agents that reduce or slow-down an aging phenotype.
|
|
WO/2019/238254A1 |
Present invention relates to a herbal composition for the treatment of urolithiasis (kidney stones), and prophylaxis of re-formation of stones after passing them, for the treatment of gout, and for inhibition of excessive amount of salts...
|
|
WO/2019/236552A1 |
Methods and compositions for treating cyanide, sulfide, or methane-thiol exposure in a subject. The compositions may include one or more cobinamide compounds, such as an amino-tetrazole-cobinamide and/or a di-(amino-tetrazole)-cobinamide.
|
|
WO/2019/235577A1 |
[Problem] The problem is to provide a medicine or the like which can prevent or treat a disease induced by oxidative stress. [Solution] A prophylactic or therapeutic agent for a disease induced by oxidative stress, a pharmaceutical compo...
|
|
WO/2019/232294A1 |
Metal-chelating compositions having the structure (1a) wherein: R1, R2, R3, and R4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (i...
|
|
WO/2019/230509A1 |
The present invention provides a reactive oxygen production inhibitor and/or scavenging promoter, and relates to a reactive oxygen production inhibitor and/or scavenging promoter that contains, as an active ingredient, a peptide having a...
|
|
WO/2019/222788A1 |
The present invention provides a method of inhibiting an effect of a noxious insult, such as an ischaemia-reperfusion injury, to an organ of a subject, the method comprising administering zinc, or a pharmaceutically acceptable salt there...
|
|
WO/2019/213756A1 |
Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated ...
|
|
WO/2019/213335A1 |
The invention generally relates to orally bioavailable prodrugs of Edaravone (including analogs, derivatives, and salts thereof) with altered pharmacokinetic properties and methods of use thereof.
|
|
WO/2019/211960A1 |
One composite composition according to the present invention includes: silicon fine particles; and a silicon sub-oxide (SiOX, where x in the formula is 1/2, 1, or 3/2) and/or a mixed composition of the silicon sub-oxide and silicon dioxi...
|
|
WO/2019/209224A2 |
The present invention relates to topical compositions that contain Butyrospermum Parkii (shea) butter and at least one excipient obtained from Helianthus annuus. The invention also relates to the use of these compositions in the treatmen...
|
|
WO/2019/205506A1 |
Provided is egg-shaped Bacteroides, the accession number thereof being GDMCC No: 60343. Further provided is a pharmaceutical composition comprising the bacterium, which is used for reducing the content of pro-inflammatory factors in the ...
|
|
WO/2019/205662A1 |
A C. militaris medium polysaccharide, a method for separating and purifying same, and the use of same. Said polysaccharide comprises the following monosaccharides in mole percentages: 0.11% ribose, 0.11% rhamnose, 0.45% arabinose, 0.13% ...
|
|
WO/2019/205505A1 |
Provided are bacteroides fragilis CCFM1020 for relieving endotoxin infection, and an application thereof. The bacteroides fragilis has low immunogenicity, and can reduce the content of proinflammatory factors in the blood of a host infec...
|
|
WO/2019/204381A1 |
Veterinary thick gel composition of high palatability containing antioxidants to decrease sarcopenia, osteopenia and DNA damage from oxidative stress in dogs, which consists of the combination of at least two antioxidants selected from: ...
|
|
WO/2019/201430A1 |
The present invention relates to the use of caffeic acid oligomeric forms in the preparation of a sustained energy release food, feed, nutraceutical and/or drink composition simultaneously providing maximal tissue protection by neutraliz...
|
|
WO/2019/201937A1 |
The present invention relates to a composition comprising a mixture of empty liposomes, wherein said mixture of empty liposomes comprises (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30...
|
|
WO/2019/204582A1 |
Methods are provided for treating a subject having, or at risk of, a lysosomal storage disease, particularly Tay-Sachs, Gaucher disease, Sandhoff disease or Niemann-Pick disease, neuronal ceroid lipofuscinosis, or a condition associated ...
|
|
WO/2019/195467A1 |
Isotopically modified polyunsaturated fatty acid or ester thereof, such as 11,11-D2-linoleic acid or its ethyl ester, and uses of the same for treating or ameliorating the symptoms of Friedreich's ataxia are disclosed.
|
|
WO/2019/189380A1 |
Provided is a TRP channel activity inhibitor capable of effectively inhibiting the activity of TRP channels, wherein the TRP channel activity inhibitor is characterized by containing aluminum ions as an active ingredient for inhibiting t...
|
|
WO/2019/183835A1 |
Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound 1 and its salts (such as sodium, potassium, and calcium salt), as well as methods of pr...
|
|
WO/2019/185942A1 |
The present invention is directed towards the use of at least one compound of formula (I) wherein R1, R2 and R3 are independently from each other H or C1-4 -alkyl, as antioxidants, especially in feed such as pet food and feed ingredients...
|
|
WO/2019/185940A1 |
The present invention is directed towards the use of at least one compound of formula (I) wherein R1, R2 and R3 are independently from each other H or linear C1-6- alkyl or branched C3-8-alkyl, as antioxidant, especially in feed such as ...
|
|
WO/2019/185939A1 |
The present invention is directed towards the use of at least one compound of formula (I) wherein R1, R2 and R3 are independently from each other H or linear C1-6-alkyl or branched C3-8-alkyl, as antioxidant in PUFA-containing edible oil...
|
|
WO/2019/185593A1 |
The present invention relates to polypeptides having myotoxin-neutralizing properties and their use for treatment of envenomation. The present invention further relates to methods for neutralizing a venom using the polypeptide of the inv...
|
|
WO/2019/189795A1 |
To provide a method for producing a large amount of novel yeast-derived microparticles at once without using any special device or reagent, provided is a method that comprises: step (A1) for heating a yeast suspension in which a yeast is...
|
|
WO/2019/177142A1 |
The present invention provides: a prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation; a cell protection agent for transplantation; and a bio-preservation agent. A prophylactic or therapeut...
|
|
WO/2019/090003A9 |
Provided herein are chimeric antigen receptors (CARs), comprising an extracellular BCMA-binding domain, in particular a scFv. The CAR also comprises a spacer of at least 125 amino acids in length, a transmembrane domain, and an intracell...
|
|
WO/2019/174003A1 |
Disclosed are Lactobacillus plantarum CCFM1019, a fermented food thereof and the use of same in preparing a drug. The bacterium is not only superior to the resident intestinal flora Escherichia coli and Enterococcus faecalis, but is also...
|
|
WO/2019/169484A1 |
Doxorubicin (Dox), a potent anti-cancer drug, can cause cardiac dysfunction and failure. Endogenous Fibroblast Growth Factor-2 (FGF2), a protein implicated in cardioprotection, regulates cardiac vulnerability to Dox. In wild type mice an...
|
|
WO/2019/172454A1 |
[Problem] To provide an emulsion composition with which it is possible to improve the absorption of various carotenoids into the body, the emulsion composition having excellent compatibility with soft capsules so as to enable soft-capsul...
|
|
WO/2019/173159A1 |
Provided herein are methods and compositions for maintaining and/or increasing vitamin C in a cell or organism. The methods and compositions are based, in part, on the synergistic effect of ergothioneine, or a derivative thereof, on vita...
|
|
WO/2019/172747A1 |
The present invention relates to processes and composition meant for delaying ageing process in a subject comprising of palm fruit juice whole or its fractions, alone or in combination with other components in the form of a composition. ...
|
|
WO/2019/166475A1 |
The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use...
|
|
WO/2019/167663A1 |
The purpose of the present invention is to provide a reduced coenzyme Q10-containing composition which is highly soluble in water and has an excellent storage stability and a method for producing the same. Provided are: a powdery composi...
|
|
WO/2019/167177A1 |
The problem addressed by the present invention is to obtain a yeast culture having improved properties such as odor and color and to use the yeast culture as an aqueous base of a cosmetic having a skin condition-improving action. A topic...
|
